Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants-Reference-Cited by-同舟云学术

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

Published:2016-03-10 Issue:10 Volume:127 Page:1325-1335
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chachoua Ilyas¹²,Pecquet Christian¹²,El-Khoury Mira³⁴⁵,Nivarthi Harini⁶,Albu Roxana-Irina¹²,Marty Caroline³⁴⁵,Gryshkova Vitalina¹²,Defour Jean-Philippe¹²,Vertenoeil Gaëlle¹²,Ngo Anna⁷,Koay Ann⁷,Raslova Hana³⁴⁵,Courtoy Pierre J.²,Choong Meng Ling⁷,Plo Isabelle³⁴⁵,Vainchenker William³⁴⁵,Kralovics Robert⁶,Constantinescu Stefan N.¹²

Affiliation:

1. Ludwig Institute for Cancer Research Brussels, Brussels, Belgium;

2. Université Catholique de Louvain and de Duve Institute, Brussels, Belgium;

3. INSERM, Unité Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France;

4. Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France;

5. Gustave Roussy, Unité Mixte de Recherche 1170, Villejuif, France;

6. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; and

7. Experimental Therapeutics Center, Singapore

Abstract

Key Points Calreticulin mutants responsible for myeloproliferative neoplasms specifically activate the thrombopoietin receptor and in turn JAK2. Activation of the thrombopoietin receptor requires the glycan binding site and a novel C-terminal tail of the mutant calreticulin.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/10/1325/1392277/1325.pdf

Reference45 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.;Vardiman;Blood,2009

2. JAK/STAT signaling in hematological malignancies.;Vainchenker;Oncogene,2013

3. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.;Cazzola;Blood,2014

4. New mutations and pathogenesis of myeloproliferative neoplasms.;Vainchenker;Blood,2011

5. Somatic mutations of calreticulin in myeloproliferative neoplasms.;Klampfl;N Engl J Med,2013

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms;International Journal of Molecular Sciences;2024-09-12

2. The CALR mutations enhance the expression of the immunosuppressive proteins GARP and LAP on peripheral blood lymphocytes through increased binding of activated platelets;British Journal of Haematology;2024-08-20

3. The sweet symphony of N-glycans in myeloid malignancies;Frontiers in Hematology;2024-07-08

4. Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms;Blood Advances;2024-06-26

5. “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity;Cancer Communications;2024-06-23